WC500185968

1. Introduction
1.1. Welcome and declarations of interest of members, alternates and
experts
The Chairperson opened the 9-12 March 2015 meeting by welcoming all participants.
Based on the declarations of interest submitted by the Committee members, alternates and experts
and based on the topics in the agenda of the current meeting, the Committee Secretariat announced
the restricted involvement of some Committee members in upcoming discussions; in accordance with
the Agency’s policy on the handling of conflicts of interests, participants in this meeting were asked to
declare any changes, omissions or errors to their declared interests concerning the matters for
discussion (see Annex II). No new or additional conflicts were declared.
Discussions, deliberations and voting took place in full respect of the restricted involvement of
Committee members and experts in line with the relevant provisions of the Rules of Procedure. All
decisions taken at this meeting were made in the presence of a quorum of members (i.e. 24 or more
members were present in the room). All decisions, recommendations and advice were agreed
unanimously, unless otherwise specified.
The PRAC Chair noted that Andis Lacis had stepped down as member for Latvia and thanked him on
behalf of the committee for his contribution to the work of the PRAC since its establishment.
1.2. Adoption of agenda of the meeting of 09-12 March 2015
The agenda was adopted with some modifications upon request from the members of the Committee
and the EMA secretariat.
1.3. Minutes of the previous PRAC meeting on 09-12 February 2015
The minutes were adopted with some amendments received during the consultation phase and will be
published on the EMA website.
Post-meeting note: the PRAC minutes of the meeting held on 9-12 February 2015 were published on
the EMA website on 27 March 2015 (EMA/PRAC/209591/2015).
2. EU Referral Procedures for Safety Reasons: Urgent EU
Procedures
2.1. Newly triggered procedures
None
2.2. Ongoing Procedures
None
2.3. Procedures for finalisation
None
Pharmacovigilance Risk Assessment Committee (PRAC)
EMA/PRAC/257790/2015 Page 11/89